Basel, Switzerland — Novartis announced significant advancements in its development of ianalumab, a treatment for Sjögren’s disease, following the successful completion of two global Phase III trials. The NEPTUNUS-1 and NEPTUNUS-2 studies showed promising results, with participants experiencing notable reductions in disease activity, marking a historic achievement in treatment options for this autoimmune disorder.

Ianalumab, which operates through a dual mechanism targeting B cells, has the potential to become the first approved therapy specifically addressing Sjögren’s disease. This condition, known for causing debilitating symptoms and often going undiagnosed, affects the exocrine glands, leading to chronic dryness in patients. According to Dr. Shreeram Aradhye, Chief Medical Officer at Novartis, the trial results highlight an urgent need for targeted therapies, as existing treatment options remain limited.

Both trials successfully met their primary endpoint, demonstrating statistically significant enhancements in disease activity metrics, specifically utilizing the EULAR Sjögren’s syndrome disease activity index (ESSDAI). Long-term follow-up for participants is encouraged, providing a comprehensive understanding of the drug’s effectiveness and safety profile. The drug was well tolerated throughout the studies, adding reassurance to its potential market introduction.

The NEPTUNUS-1 trial involved 275 participants and compared ianalumab’s 300 mg subcutaneous dosage to a placebo over 52 weeks. In parallel, the NEPTUNUS-2 trial, which enrolled 504 subjects, assessed the same dosage administered monthly and every three months. The positive outcomes from both studies paved the way for Novartis to approach health authorities regarding the drug’s approval.

Sjögren’s disease is recognized for its significant impact on quality of life and is predominantly prevalent among women, with many cases remaining undiagnosed. The disorder frequently manifests with dry eyes and mouth, but can also lead to more severe extraglandular conditions that affect various organs, underscoring a pressing need for safer and more effective treatments.

Currently, no systemic treatments are approved for this disease, which complicates the lives of approximately 0.25% of the population. The research and development behind ianalumab could fill a substantial gap, as cited studies reveal that a significant portion of patients experiences ongoing symptoms despite available symptomatic therapies.

The promising data stemming from these trials positions ianalumab as a potential game-changer in autoimmune care. Novartis plans to present findings from the NEPTUNUS studies at an upcoming medical congress, aiming to establish a pathway for swift global regulatory submissions given the urgency felt by healthcare providers and patients alike.

As the pharmaceutical industry looks ahead, Novartis continues its commitment to innovative treatments that can improve patient outcomes. The company’s efforts in the realm of autoimmune diseases, especially through the development of ianalumab, may soon lead to revolutionary shifts in how Sjögren’s and similar disorders are managed.